Age and APOEε4 correlate with cognitive improvement after Lecanemab treatment.
Although no significant cognitive score improvement was observed in the 26 Chinese patients after six months of treatment with lecanemab, improvements were seen in plasma biomarkers pTau181 and NfL. Plasma Aβ42 and Aβ40 significantly increased, suggesting altered Aβ protein metabolism through the bloodstream. Age and APOEε4 carrier status impacted cognitive improvement.
Authors
- Yulei Deng (ORCID: https://orcid.org/0000-0002-9564-2609)
- Yingting Zheng
- Binyin Li
- Xinyuan Yang
- Lin Kang
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104146
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00